Auto-generated from public data. Not the firm's stated position.
Based on disclosed data, Vesalius Biocapital Partners appears to focus primarily on early-to-growth stage biotech companies addressing therapeutic areas including autoimmune disease, neurodegenerative conditions, and women's health, despite fintech being listed as a disclosed sector. Recent portfolio suggests a concentration in life sciences rather than financial technology, with check sizes starting at €3.0M across a substantial fund base.
Generated 4 Aug 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
€200k – €10M
Auto-detected from Vesalius Biocapital Partners's website.
Seasoned life science professional with deep expertise in start-up maturation.
PhD with extensive experience in maturing start-up companies through technical and business insights.
PhD with extensive experience in maturing start-up companies through technical and business insights.
Seasoned life science professional with deep expertise in start-up maturation.
Seasoned life science professional with deep expertise in start-up maturation.
Website reachable as of Aug 2026. Focus and check size as listed by the firm, not independently verified.
Learn what Vesalius Biocapital Partners and similar investors look for:
Fintech pitch guideTips, programs, and cultural notes
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.